Comparison of melanoma antigens in whole tumor extracts to those from IIB-MEL-J cells

J. M.C. McGee, M. R. Patten, K. F. Malnar, J. A. Price, J. S. Mayes

Research output: Contribution to journalArticle

Abstract

Immunotherapy for melanoma has shown promise. A previous crude tumor extract (TE) was noted to have positive clinical effects and was previously analyzed with Western Blots. A new, safer vaccine derived from IIB-MEL-J tissue culture (TC) is compared to TE. Sera from 12 vaccine recipients, 8 melanoma patients who received no immunotherapy, and 8 normal controls served as a source of antibodies to investigate antigens in the vaccines. Antibodies against one or more of 6 antigens with molecular masses of 147, 81, 43, 37. 35, and 33 kDa were found in patient sera, were reactive to both vaccines, and were minimal in control sera. The molecular mass of antigens In TC are similar to TE. This new vaccine from IIB-MEL-J tissue culture provides a higher yield and a much more consistent source of clinically relevant antigens without risk of infection or contamination by other irrelevant material. This new source of antigen can be combined with biologic response modifiers to initiate further clinical trials.

Original languageEnglish
Pages (from-to)A441
JournalFASEB Journal
Volume10
Issue number3
StatePublished - 1 Dec 1996

Fingerprint

Melanoma-Specific Antigens
Tumors
Vaccines
Tissue culture
Antigens
Molecular mass
Neoplasms
Immunotherapy
Melanoma
Serum
Antibodies
Complex Mixtures
Contamination
Western Blotting
Clinical Trials
Infection

Cite this

McGee, J. M. C., Patten, M. R., Malnar, K. F., Price, J. A., & Mayes, J. S. (1996). Comparison of melanoma antigens in whole tumor extracts to those from IIB-MEL-J cells. FASEB Journal, 10(3), A441.
McGee, J. M.C. ; Patten, M. R. ; Malnar, K. F. ; Price, J. A. ; Mayes, J. S. / Comparison of melanoma antigens in whole tumor extracts to those from IIB-MEL-J cells. In: FASEB Journal. 1996 ; Vol. 10, No. 3. pp. A441.
@article{05b0e392d8074eee92c98ca21a425cbd,
title = "Comparison of melanoma antigens in whole tumor extracts to those from IIB-MEL-J cells",
abstract = "Immunotherapy for melanoma has shown promise. A previous crude tumor extract (TE) was noted to have positive clinical effects and was previously analyzed with Western Blots. A new, safer vaccine derived from IIB-MEL-J tissue culture (TC) is compared to TE. Sera from 12 vaccine recipients, 8 melanoma patients who received no immunotherapy, and 8 normal controls served as a source of antibodies to investigate antigens in the vaccines. Antibodies against one or more of 6 antigens with molecular masses of 147, 81, 43, 37. 35, and 33 kDa were found in patient sera, were reactive to both vaccines, and were minimal in control sera. The molecular mass of antigens In TC are similar to TE. This new vaccine from IIB-MEL-J tissue culture provides a higher yield and a much more consistent source of clinically relevant antigens without risk of infection or contamination by other irrelevant material. This new source of antigen can be combined with biologic response modifiers to initiate further clinical trials.",
author = "McGee, {J. M.C.} and Patten, {M. R.} and Malnar, {K. F.} and Price, {J. A.} and Mayes, {J. S.}",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "10",
pages = "A441",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "3",

}

McGee, JMC, Patten, MR, Malnar, KF, Price, JA & Mayes, JS 1996, 'Comparison of melanoma antigens in whole tumor extracts to those from IIB-MEL-J cells', FASEB Journal, vol. 10, no. 3, pp. A441.

Comparison of melanoma antigens in whole tumor extracts to those from IIB-MEL-J cells. / McGee, J. M.C.; Patten, M. R.; Malnar, K. F.; Price, J. A.; Mayes, J. S.

In: FASEB Journal, Vol. 10, No. 3, 01.12.1996, p. A441.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of melanoma antigens in whole tumor extracts to those from IIB-MEL-J cells

AU - McGee, J. M.C.

AU - Patten, M. R.

AU - Malnar, K. F.

AU - Price, J. A.

AU - Mayes, J. S.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Immunotherapy for melanoma has shown promise. A previous crude tumor extract (TE) was noted to have positive clinical effects and was previously analyzed with Western Blots. A new, safer vaccine derived from IIB-MEL-J tissue culture (TC) is compared to TE. Sera from 12 vaccine recipients, 8 melanoma patients who received no immunotherapy, and 8 normal controls served as a source of antibodies to investigate antigens in the vaccines. Antibodies against one or more of 6 antigens with molecular masses of 147, 81, 43, 37. 35, and 33 kDa were found in patient sera, were reactive to both vaccines, and were minimal in control sera. The molecular mass of antigens In TC are similar to TE. This new vaccine from IIB-MEL-J tissue culture provides a higher yield and a much more consistent source of clinically relevant antigens without risk of infection or contamination by other irrelevant material. This new source of antigen can be combined with biologic response modifiers to initiate further clinical trials.

AB - Immunotherapy for melanoma has shown promise. A previous crude tumor extract (TE) was noted to have positive clinical effects and was previously analyzed with Western Blots. A new, safer vaccine derived from IIB-MEL-J tissue culture (TC) is compared to TE. Sera from 12 vaccine recipients, 8 melanoma patients who received no immunotherapy, and 8 normal controls served as a source of antibodies to investigate antigens in the vaccines. Antibodies against one or more of 6 antigens with molecular masses of 147, 81, 43, 37. 35, and 33 kDa were found in patient sera, were reactive to both vaccines, and were minimal in control sera. The molecular mass of antigens In TC are similar to TE. This new vaccine from IIB-MEL-J tissue culture provides a higher yield and a much more consistent source of clinically relevant antigens without risk of infection or contamination by other irrelevant material. This new source of antigen can be combined with biologic response modifiers to initiate further clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33749142938&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749142938

VL - 10

SP - A441

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 3

ER -